PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD

Oct 5, 2026 · 0:07:14
Listen to Episode
✨ AI Summary
  • Enlicitide, an oral PCSK9 inhibitor, is approved for hypercholesterolemia.
  • It offers an alternative to injectables but lacks a CV indication.
  • Use is limited to an add-on therapy to statins.

Guests on This Episode

NH
Ninel Hovnanians
researcher · 1 podcast appearance
›

More from HCPLive

HCPLive
Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites
Oct 12, 2026 · 0:03:18
HCPLive
Targeting Senescent Cells in Actinic Keratosis With RLS-1496
Oct 12, 2026 · 0:04:25
HCPLive
Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD
Oct 12, 2026 · 0:03:33
HCPLive
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Oct 12, 2026 · 0:06:00
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →